Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) released topline results from Part 2 of a Phase 1/2 study of ARO-C3, the ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced presentation of preclinical data supporting the advancement of ...

Arrowhead (ARWR) announced topline results from Part 2 of a Phase 1/2 clinical study of ARO-C3, the company’s investigational RNA interference ...

Arrowhead (ARWR) announced presentation of preclinical data supporting the advancement of two clinical stage, RNAi-based investigational ...

Duration of effect supportive of once every three months or less frequent subcutaneous dosing in later-stage studies Effects ... Drug Administration accepted Arrowhead Pharmaceuticals’ New ...

Arrowhead believes it is the first company to initiate clinical studies against these two novel targets, INHBE and ALK7. INHBE, and the ligand it encodes Activin E, signals the ALK7 receptor on ...

“Arrowhead is leading the field in the discovery and development of potential new RNAi-based therapies for obesity and metabolic diseases. Our first two programs, ARO-INHBE and ARO ...

March 06, 2025--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced presentation of preclinical data supporting the advancement of two first-in-class clinical stage ...